Athens University Medical School, 1st Department of Psychiatry, Eginition Hospital, Athens, Greece.
The present study compared the efficacy of agomelatine and sertraline in the treatment of symptoms of depression/anxiety, diabetes self-care and metabolic control in a sample of depressed patients with non-optimally controlled type 2 diabetes mellitus (DM).
This was an observational open label study of 40 depressed patients with DM who were randomly assigned to receive either agomelatine or sertraline, and were assessed over a 4-month period for depression, anxiety, self-care, fasting plasma glucose,空腹血糖 haemoglobin A1c 糖化血红蛋白 and body weight.
Lower anxiety and depression scores as well as higher self-care scores were measured in the agomelatine group compared with the sertraline group after 4 months of treatment. Although the main effects of treatment on final body weight and fasting plasma glucose were not significant, significantly lower final haemoglobin A1c levels were measured in the agomelatine group compared with the sertraline group. Both antidepressants were well tolerated and none of the patients dropped-out of the study.
1、4个月的治疗后，阿戈美拉汀组焦虑与抑郁分数较舍曲林组更低，自理分数更高
2、阿戈美拉汀组较舍曲林组糖化血红蛋白水平更低
The main finding of the present small pilot study was that agomelatine may be a promising agent in the treatment of symptoms of depression and anxiety as well as in the improvement of health-related behaviours, in depressed patients with type 2 DM possibly offering some advantages over sertraline. However, the lack of a placebo control group limits the generalisability of the findings and warrants further studies.
阿戈美拉汀对比舍曲林，对于改善2型糖尿病患者的抑郁与焦虑症状，与此同时，改善健康相关的情况均具有相应的优势。
但是本研究缺少安慰剂组的对照。
© 2013 Blackwell Publishing Ltd.
PMID: 23409693 [PubMed - in process]
